FHIR Implementation Guide for NJSAMS
1.0.0 - release
1.0.0 - release
NJSAMS - Local Development build (v1.0.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: https://fhir.njsams.rutgers.edu/NJSAMS-fhir/Questionnaire/OTP | Version: 1.0.0 | |||
| Draft as of 2022-08-31 | Computable Name: | |||
Justification for level of care score (see ServiceRequest) in Opioid Treatment Program
Generated Narrative: Questionnaire OTP
| LinkID | Text | Cardinality | Type | Description & Constraints |
|---|---|---|---|---|
  | Justification for level of care score (see ServiceRequest) in Opioid Treatment Program | Questionnaire | https://fhir.njsams.rutgers.edu/NJSAMS-fhir/Questionnaire/OTP#1.0.0 | |
  LOCI3OTPDimension | null | 0..1 | group | |
   LOCI3OTPDimension.Dimension1 | a.1. Maintenance treatment :An OTP shall maintain current procedures designed to ensure patients are admitted to agonist treatment by qualified personnel who have determined the person is currently addicted to an opioid drug, and that the person became addicted at least 1 year before admission for treatment. In addition, program physician shall ensure each patient voluntarily chooses maintenance treatment and that all relevant facts concerning the use of the opioid drug are clearly and adequately explained to patient, and that each patient provides informed written consent to treatment. b.2. Agonist treatment for persons under age 18 :A person under 18 years of age is required to have had two documented unsuccessful attempts at short-term withdrawal management or drug-free treatment within a 12-month period to be eligible for agonist treatment. No person under 18 years may be admitted to maintenance treatment unless parent, legal guardian, or responsible adult designated by relevant state authority consents in writing to such treatment. c.3. Agonist treatment admission exceptions : If clinically appropriate, program physician may waive requirement of 1-year history of addiction under part (e), paragraph (1), of 42 CFR 8.12, for patients released from penal institutions (within 6 months after release), for pregnant patients, and for previously treated patients (up to 2 years after discharge). d. [42 CFR 8.2] “Opioid addiction” is described in 42 CFR 8.2 as a cluster of cognitive, behavioral, and physiological symptoms in which the individual continues use of opioids despite significant opioid-induced problems. Opioid use disorder is characterized by repeated self-administration that usually results in opioid tolerance,withdrawal symptoms, and compulsive drug taking.Addiction involving the use of opioids is defined by ASAM through the ASAM Definition of Addiction. e. Opioid use disorder may occur with or without the physiological symptoms of tolerance and withdrawal. f. Patient’s current physiological dependence (in addition to a history of addiction) is confirmed by vital signs,early physical signs of narcotic withdrawal, a urine screen that is positive for opioids, the presence of old or fresh needle marks, and documented reports from medical professionals, patient or family, treatment history, or a positive reaction to a naloxone test. | 1..1 | boolean | |
| LOCI3OTPDimension.Dimension2a | b. No Meets the biomedical criteria for opioid use disorder, with or without complications of opioid addiction requires outpatient medical monitoring and skilled care OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension2b | b. No Concurrent biomedical illness or pregnancy, which can be treated on outpatient basis with minimal daily medical monitoring OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension2c | b. No Biomedical problems that can be managed on outpatient basis. | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension3a | a. Emotional, behavioral, or cognitive problems, if present, are manageable in an outpatient structured environment OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension3b | b. Substance-related use or neglect of spouse, children, or significant others requires intensive outpatient treatment to reduce risk of further deterioration OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension3c | c. A diagnosed stable emotional, behavioral, or cognitive problem or thought disorder that requires monitoring, management, or medication because of the risk that problem[s] will distract patient from treatment OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension3d | d. A mild risk of harm to self or others, with or without a history of severe depression, suicidal or homicidal behavior, but can be managed safely in a structured outpatient environment OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension3e | e. Demonstrates emotional and behavioral stability but requires continued pharmacotherapy to prevent relapse. | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension4a | a. Requires structured therapy, pharmacotherapy, and programmatic milieu to promote treatment progress and recovery OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension4b | b. Attributes problems to persons or external events rather than to substance-related disorder, thus uninterested in making behavioral changes in the absence of clinically directed and repeated structured motivational interventions. However, low interest in recovery does not render treatment ineffective. | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension5a | a. Requires structured therapy, pharmacotherapy, and a programmatic milieu to promote treatment progress because patient attributes continued relapse to physiologic craving or the need for opioids OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension5b | b. Despite active participation in other treatment interventions without provision for opioid pharmacotherapy, patient is experiencing an intensification of addiction symptoms or continued high-risk behaviors, and level of functioning is deteriorating, despite revisions of treatment plan OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension5c | c. At high risk of relapse to opioid use without opioid pharmacotherapy, close outpatient monitoring, and structured support | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension5d | d. Pregnant and requires continued opioid pharmacotherapy to avert repeated episodes of withdrawal by the fetus and ensure its continued health. | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension6a | a. A sufficiently supportive psychosocial environment to render opioid pharmacotherapy feasible OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension6b | b. Family members or significant others are supportive,but requires professional intervention to improve patient likelihood of treatment success OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension6c | c. Does not have a positive social support system to assist with immediate recovery efforts, but has demonstrated motivation to obtain such support system or to pursue an appropriate alternative living environment OR | 0..1 | boolean | |
| LOCI3OTPDimension.Dimension6d | d. Has experienced traumatic events in recovery environment or has manifested effects of emotional,behavioral, or cognitive problems in the environment,but these are manageable on an outpatient basis. | 0..1 | boolean | |
| Documentation for this format | ||||